SecProbe.io

<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>

Mail Stop 6010

								July 28, 2005

Evan Levine
Chief Executive Officer
ADVENTRX Pharmaceuticals, Inc.
6725 Mesa Ridge Road, Suite 100
San Diego, California 92121

	Re:	ADVENTRX Pharmaceuticals, Inc.
		Form 10-KSB for the Year Ended December 31, 2004
		Proxy Statement filed May 20, 2005
		File No. 1-32157

Dear Mr. Levine:

	We have reviewed your filing and have the following comments.
Where indicated, we think you should revise your document in
response
to these comments.  If you disagree, we will consider your
explanation
as to why our comment is inapplicable or a revision is
unnecessary.
Please be as detailed as necessary in your explanation.  In some
of
our comments, we may ask you to provide us with information so we
may
better understand your disclosure.  After reviewing this
information,
we may raise additional comments.

	Please understand that the purpose of our review process is
to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We
look forward to working with you in these respects.  We welcome
any
questions you may have about our comments or any other aspect of
our
review.  Feel free to call us at the telephone numbers listed at
the
end of this letter.

FORM 10-KSB

Risk Factors, page 19

1. Many of your risk factors could apply to any issuer.  Please
ensure
that all risk factors in your filing describe your company`s
circumstances with specificity.  We note the following examples:

* In "It is uncertain that we will have access to future capital
or
government grants" on page 19, please describe the difficulties
you
would need to overcome to obtain a government grant.
* In "We are not certain that we will be successful . . ." on page
19,
please describe any material delays or difficulties your products
have
experienced in the development process.
* In "We will face intense competition from other companies in the
pharmaceutical industry" on page 20, please identify your
principal
competitors and their products that compete with yours.
* In "Uncertainties related to health care reform measures may
affect
our success" on page 21, please identify any reform proposals that
would materially affect on your business, and state where these
proposals stand in the enactment process.
* If you have received notice of another company`s belief that you
are
infringing their patent, or if you have notified another company
of
your belief that they are infringing on your patents, please
describe
the situation and potential consequences in "Protecting our
proprietary rights is difficult and costly" on page 23.
* Please identify the key personnel you refer to in "Our success
is
dependent on our key personnel" and "We may be unable to retain
skilled personnel and maintain key relationships" on page 23, and
state whether you have written employment agreements with these
individuals.

With the above guidance in mind, please re-evaluate all risk
factors
and tailor them more to your company.

Power of Attorney, page 35

2. We note the filing does not include the signature of your
controller or principal accounting officer.  Please include this
signature in an amended Form 10-KSB.  If Carrie Carlander, the
CFO,
also serves as the controller or principal accounting officer, her
signature should be captioned as such in your amended filing.  See
General Instruction C.2 of Form 10-KSB.

PROXY STATEMENT

Certain Relationships and Related Transactions, page 12

3. It appears you did not file as an exhibit your agreement with
Burnham Hill Partners.  Please file this agreement with your
amended
Form 10-KSB.  See Item 601(b)(10)(i)(A) of Regulation S-B.

*	*	*

	As appropriate, please amend your filing and respond to these
comments within 10 business days or tell us when you will provide
us
with a response.  You may wish to provide us with marked copies of
the
amendment to expedite our review.  Please furnish a cover letter
with
your amendment that keys your responses to our comments and
provides
any requested information.  Detailed cover letters greatly
facilitate
our review.  Please understand that we may have additional
comments
after reviewing your amendment and responses to our comments.

	We urge all persons who are responsible for the accuracy and
adequacy of the disclosure in the filing to be certain that the
filing
includes all information required under the Securities Exchange
Act of
1934 and that they have provided all information investors require
for
an informed investment decision.  Since the company and its
management
are in possession of all facts relating to a company`s disclosure,
they are responsible for the accuracy and adequacy of the
disclosures
they have made.

	In connection with responding to our comments, please
provide, in
writing, a statement from the company acknowledging that:

* the company is responsible for the adequacy and accuracy of the
disclosure in the filing;

* staff comments or changes to disclosure in response to staff
comments do not foreclose the Commission from taking any action
with
respect to the filing; and

* the company may not assert staff comments as a defense in any
proceeding initiated by the Commission or any person under the
federal
securities laws of the United States.

	In addition, please be advised that the Division of
Enforcement
has access to all information you provide to the staff of the
Division
of Corporation Finance in our review of your filing or in response
to
our comments on your filing.

	Please contact Greg Belliston at (202) 551-3861 or me at
(202)
551-3715 with any questions.

								Sincerely,

								Jeffrey Riedler
								Assistant Director
??

??

??

??

Evan Levine
ADVENTRX Pharmaceuticals, Inc.
July 28, 2005
Page 1

</TEXT>
</DOCUMENT>